Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics announced today that The Lancet has published clinical data evaluating ISIS-APO(a)Rx in healthy volunteers …
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that it has initiated a Phase 1/2a clinical study of ISIS-HTTRx in patients with Huntington’s disease (HD).
Bank of America Corp (NYSE:BAC) shares increased 2.74% to $17.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced today that it has earned a $2.
Akcea Therapeutics, a wholly-owned subsidiary of ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), announced that the U.
Isis Pharmaceuticals It can be very difficult to find companies that are both flying under the radar, and still might have potential for …
Needham analyst Chad Messer came out with commentary on ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) following recent updates from two ongoing Phase II studies with ISIS-SMNRx, a drug to …
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMNRx …
Piper Jaffray analyst Joshua Schimmer came out with a research report on ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) following the company’s encouraging update from the ongoing Phase …
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMNRx in infants with Type I spinal …
